Human Endogenous Retrovirus K in Cancer: A Potential Biomarker and Immunotherapeutic Target.

Tytuł:: Human Endogenous Retrovirus K in Cancer: A Potential Biomarker and Immunotherapeutic Target.
Autorzy:: Curty G; Programa de Oncovirologia, Instituto Nacional de Câncer, Rio de Janeiro RJ 20231-050, Brazil.
Marston JL; Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA.
de Mulder Rougvie M; Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA.
Leal FE; Programa de Oncovirologia, Instituto Nacional de Câncer, Rio de Janeiro RJ 20231-050, Brazil.
Nixon DF; Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA.
Soares MA; Programa de Oncovirologia, Instituto Nacional de Câncer, Rio de Janeiro RJ 20231-050, Brazil.
Źródło:: Viruses [Viruses] 2020 Jul 06; Vol. 12 (7). Date of Electronic Publication: 2020 Jul 06.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
Język:: English
Imprint Name(s):: Original Publication: Basel, Switzerland : MDPI
MeSH Terms:: Endogenous Retroviruses*/genetics
Endogenous Retroviruses*/immunology
Immunotherapy/*methods
Neoplasms/*virology
Biomarkers, Tumor/immunology ; Genome, Viral/genetics ; Humans ; Neoplasms/immunology ; Neoplasms/therapy
References:: J Gen Virol. 1984 May;65 ( Pt 5):887-98. (PMID: 6202829)
Mob DNA. 2018 Dec 18;9:36. (PMID: 30568734)
Retrovirology. 2016 Feb 06;13:10. (PMID: 26852322)
Cell Mol Life Sci. 2017 Jun;74(11):2055-2065. (PMID: 28160052)
AIDS Res Hum Retroviruses. 2004 Nov;20(11):1223-9. (PMID: 15588344)
Carcinogenesis. 2013 Nov;34(11):2531-8. (PMID: 23872666)
J Virol. 2019 Jul 30;93(16):. (PMID: 31167914)
Nat Med. 2010 May;16(5):571-9, 1p following 579. (PMID: 20436485)
Oncoimmunology. 2015 May 26;4(11):e1047582. (PMID: 26451325)
Elife. 2018 Aug 02;7:. (PMID: 30070637)
Leukemia. 2013 Jul;27(7):1469-78. (PMID: 23307033)
Rev Med Virol. 2019 Mar;29(2):e2025. (PMID: 30614117)
Gene. 2009 Dec 15;448(2):115-23. (PMID: 19540319)
Clin Cancer Res. 2017 Oct 1;23(19):5892-5911. (PMID: 28679769)
Carcinogenesis. 2014 Sep;35(9):2074-83. (PMID: 24858205)
J Virol. 1999 Dec;73(12):9976-83. (PMID: 10559311)
PLoS One. 2019 Feb 28;14(2):e0212970. (PMID: 30818388)
J Clin Invest. 2018 Nov 1;128(11):4804-4820. (PMID: 30137025)
J Immunol. 2014 Feb 15;192(4):1343-9. (PMID: 24511094)
Retrovirology. 2018 Aug 28;15(1):59. (PMID: 30153831)
Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14572-9. (PMID: 15310846)
PLoS One. 2013 Aug 30;8(8):e72756. (PMID: 24023643)
PLoS One. 2013 May 07;8(5):e63711. (PMID: 23667660)
Genes Cancer. 2016 Nov;7(11-12):394-413. (PMID: 28191285)
Nat Rev Microbiol. 2019 Jun;17(6):355-370. (PMID: 30962577)
Mob DNA. 2020 Feb 7;11:9. (PMID: 32055257)
J Virol. 2005 Jan;79(2):876-83. (PMID: 15613316)
J Mol Evol. 2004 Nov;59(5):642-56. (PMID: 15693620)
Neoplasia. 2008 Jun;10(6):521-33. (PMID: 18516289)
Front Oncol. 2013 Sep 26;3:255. (PMID: 24133654)
J Virol. 1999 Nov;73(11):9496-507. (PMID: 10516058)
Cancer Res. 2005 May 15;65(10):4172-80. (PMID: 15899808)
Cancer Lett. 2007 Jul 18;252(2):290-8. (PMID: 17320278)
Front Psychiatry. 2018 Sep 07;9:422. (PMID: 30245643)
Nat Genet. 2019 Apr;51(4):611-617. (PMID: 30926969)
J Virol. 2004 Oct;78(19):10310-9. (PMID: 15367597)
PLoS Comput Biol. 2016 Jun 13;12(6):e1004964. (PMID: 27295277)
J Clin Invest. 2008 Mar;118(3):1099-109. (PMID: 18292810)
J Gen Virol. 2010 Jun;91(Pt 6):1494-502. (PMID: 20147518)
Curr Top Microbiol Immunol. 2006;310:211-50. (PMID: 16909913)
Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1668-72. (PMID: 14757818)
Vaccine. 2009 Jan 22;27(4):588-91. (PMID: 19010368)
Front Oncol. 2013 Sep 20;3:246. (PMID: 24066280)
Virology. 1993 Feb;192(2):501-11. (PMID: 8421897)
Front Genet. 2018 Aug 14;9:298. (PMID: 30154825)
J Virol. 2008 Oct;82(19):9329-36. (PMID: 18632860)
Oncogene. 2005 Apr 28;24(19):3223-8. (PMID: 15735668)
Retrovirology. 2005 Aug 10;2:50. (PMID: 16092962)
Nat Rev Urol. 2014 Sep;11(9):499-507. (PMID: 25134838)
J Surg Res. 2019 Aug;240:145-155. (PMID: 30933828)
Crit Rev Microbiol. 2018 Nov;44(6):715-738. (PMID: 30318978)
Sci Rep. 2017 Feb 06;7:41960. (PMID: 28165048)
Oncogene. 2000 Sep 7;19(38):4328-36. (PMID: 10980608)
Int J Cancer. 2007 Jan 1;120(1):81-90. (PMID: 17013901)
Retrovirology. 2012 Jan 16;9:6. (PMID: 22248111)
Nat Rev Microbiol. 2012 May 08;10(6):395-406. (PMID: 22565131)
APMIS. 2016 Jan-Feb;124(1-2):67-87. (PMID: 26818263)
Mol Biol Rep. 2019 Apr;46(2):1885-1893. (PMID: 30707417)
J Virol. 2007 Jun;81(11):5607-16. (PMID: 17360752)
Retrovirology. 2018 Aug 20;15(1):57. (PMID: 30126415)
Intervirology. 1973;1(1):19-26. (PMID: 4129686)
Curr Opin Microbiol. 2016 Jun;31:176-183. (PMID: 27128186)
Trends Cell Biol. 2019 Jan;29(1):31-43. (PMID: 30153961)
Front Microbiol. 2018 Mar 14;9:462. (PMID: 29593697)
Front Microbiol. 2018 Jun 15;9:1253. (PMID: 29963023)
Mob DNA. 2016 Dec 1;7:24. (PMID: 27980689)
Biomed Res Int. 2016;2016:8201642. (PMID: 28070518)
Pigment Cell Melanoma Res. 2013 May;26(3):426-8. (PMID: 23311654)
Genes Chromosomes Cancer. 2010 May;49(5):401-11. (PMID: 20095041)
Int J Cancer. 2004 Jun 20;110(3):459-61. (PMID: 15095315)
PLoS One. 2013;8(1):e53895. (PMID: 23382858)
AIDS Res Hum Retroviruses. 2008 May;24(5):717-23. (PMID: 18462078)
Int J Mol Sci. 2016 Apr 28;17(5):. (PMID: 27136533)
J Natl Cancer Inst. 2012 Feb 8;104(3):189-210. (PMID: 22247020)
Clin Cancer Res. 2015 Jan 15;21(2):471-83. (PMID: 25370465)
Gene. 2009 Dec 15;448(2):105-14. (PMID: 19577618)
J Virol. 2001 Nov;75(21):10359-71. (PMID: 11581404)
Virol J. 2014 Mar 26;11:58. (PMID: 24669861)
Cell Cycle. 2015;14(16):2619-33. (PMID: 26103464)
Retrovirology. 2011 Nov 08;8:90. (PMID: 22067224)
Mob DNA. 2016 Aug 11;7:16. (PMID: 27525044)
Int J Gynecol Cancer. 2011 Jan;21(1):51-7. (PMID: 21330831)
Nat Rev Cancer. 2019 Aug;19(8):465-478. (PMID: 31278396)
Clin Cancer Res. 2015 Jul 15;21(14):3241-51. (PMID: 25829402)
J Gen Virol. 2015 Jun;96(Pt 6):1207-1218. (PMID: 26068187)
Nature. 2017 Aug 24;548(7668):471-475. (PMID: 28813415)
Proc Natl Acad Sci U S A. 1981 Aug;78(8):4892-6. (PMID: 6272283)
AIDS Res Hum Retroviruses. 2006 Jan;22(1):52-6. (PMID: 16438646)
Eur J Cancer. 2005 Jan;41(1):104-17. (PMID: 15617995)
Front Genet. 2019 Jun 25;10:580. (PMID: 31293617)
Curr Oncol. 2013 Jun;20(3):e270-3. (PMID: 23737697)
Front Immunol. 2018 Sep 10;9:2039. (PMID: 30250470)
Clin Cancer Res. 2002 Jun;8(6):1800-7. (PMID: 12060620)
Int J Cancer. 2014 Feb 1;134(3):587-95. (PMID: 23873154)
Cancer Res. 2008 Jul 15;68(14):5869-77. (PMID: 18632641)
Ann Oncol. 2018 Nov 1;29(11):2183-2191. (PMID: 30239576)
Nat New Biol. 1972 Nov 15;240(98):67-72. (PMID: 4117890)
Melanoma Res. 2006 Jun;16(3):223-34. (PMID: 16718269)
J Vis Exp. 2013 Nov 02;(81):e50713. (PMID: 24300377)
Cancer Res. 2006 Feb 1;66(3):1658-63. (PMID: 16452225)
Viruses. 2018 Aug 07;10(8):. (PMID: 30087231)
Expert Opin Ther Targets. 2017 Oct;21(10):921-924. (PMID: 28847189)
Cell Mol Life Sci. 2008 Nov;65(21):3366-82. (PMID: 18818873)
Trends Genet. 2007 Jul;23(7):326-33. (PMID: 17524519)
J Virol. 1995 Jan;69(1):414-21. (PMID: 7983737)
Genes Cancer. 2011 Sep;2(9):914-22. (PMID: 22593804)
Cancers (Basel). 2020 Mar 06;12(3):. (PMID: 32155827)
Cancer Res. 2003 Dec 15;63(24):8735-41. (PMID: 14695188)
J Cell Biol. 2017 Nov 6;216(11):3535-3549. (PMID: 28887438)
Proc Natl Acad Sci U S A. 1993 May 15;90(10):4480-4. (PMID: 8506289)
Mob DNA. 2011 May 04;2(1):7. (PMID: 21542922)
Mob DNA. 2017 Nov 2;8:15. (PMID: 29118853)
Infect Agent Cancer. 2019 Nov 29;14:42. (PMID: 31798679)
Front Microbiol. 2018 Feb 13;9:178. (PMID: 29487579)
Retrovirology. 2014 Aug 12;11:62. (PMID: 25112280)
Trends Cancer. 2018 Aug;4(8):583-597. (PMID: 30064665)
Genome Biol Evol. 2013;5(2):307-28. (PMID: 23338945)
Philos Trans R Soc Lond B Biol Sci. 2017 Oct 19;372(1732):. (PMID: 28893944)
Viruses. 2017 May 31;9(6):. (PMID: 28561791)
Semin Cancer Biol. 2018 Dec;53:17-30. (PMID: 30317035)
Int J Cancer. 2013 Feb 1;132(3):556-67. (PMID: 22733359)
Cancer Biol Med. 2016 Dec;13(4):483-488. (PMID: 28154780)
Clin Cancer Res. 2013 Nov 15;19(22):6112-25. (PMID: 24081977)
Carcinogenesis. 2011 Oct;32(10):1484-92. (PMID: 21828060)
Cancer Res. 2002 Oct 1;62(19):5510-6. (PMID: 12359761)
Cancer. 2003 Jul 1;98(1):187-97. (PMID: 12833471)
Cancer Res. 2016 Apr 15;76(8):2177-85. (PMID: 26862115)
Cancer Immun. 2008 Nov 13;8:15. (PMID: 19006261)
J Virol. 2000 Apr;74(7):3321-9. (PMID: 10708449)
Cell. 2015 Aug 27;162(5):974-86. (PMID: 26317466)
Viruses. 2020 May 30;12(6):. (PMID: 32486217)
Grant Information:: R01 CA206488 United States CA NCI NIH HHS; CA206488 United States NH NIH HHS
Contributed Indexing:: Keywords: HERV; HERV-K; HML-2 subtype; cancer; endogenous retrovirus; immune response; immunotherapy; neoantigen; oncogenesis; tumor-specific antigens
Substance Nomenclature:: 0 (Biomarkers, Tumor)
Entry Date(s):: Date Created: 20200710 Date Completed: 20210222 Latest Revision: 20221017
Update Code:: 20240105
PubMed Central ID:: PMC7412025
DOI:: 10.3390/v12070726
PMID:: 32640516
: Czasopismo naukowe

Pełny tekst

In diseases where epigenetic mechanisms are changed, such as cancer, many genes show altered gene expression and inhibited genes become activated. Human endogenous retrovirus type K (HERV-K) expression is usually inhibited in normal cells from healthy adults. In tumor cells, however, HERV-K mRNA expression has been frequently documented to increase. Importantly, HERV-K-derived proteins can act as tumor-specific antigens, a class of neoantigens, and induce immune responses in different types of cancer. In this review, we describe the function of the HERV-K HML-2 subtype in carcinogenesis as biomarkers, and their potential as targets for cancer immunotherapy.

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja